Perioperative Durvalumab Plus FLOT Boosts EFS in Resectable Gastric/GEJ Cancer

(MedPage Today) -- CHICAGO -- Adding perioperative durvalumab (Imfinzi) to FLOT chemotherapy significantly improved event-free survival (EFS) compared with FLOT alone in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma...